Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) NICE, (b) NHS England and (c) representatives of the pharmaceutical industry on reducing the cost-effectiveness threshold for NICE technology appraisals.

The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative medicines and technologies at a price the National Health Service can afford. The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence, as well as representatives of the pharmaceutical industry, on matters related to medicines pricing and patient access to new treatments.